Degradation of cellular proteins by the proteasome is critical for the generation of MHC-associated peptides. The constitutive proteasome and the IFNgamma-induced immunoproteasome (IP) differ in the use of three catalytic subunits, which alters production of MHC class I epitopes. The potential for a disparate repertoire of epitopes produced between inflammatory/non-inflammatory tumours therefore arises.
We have extensively investigated this phenomenon both broadly, in terms of the cancer cell as a whole, and specifically, by evaluating presentation of three NY-ESO-1 HLA-Cw3 restricted epitopes.
We profiled the immunopeptidome of a melanoma cell line under steady state or IFNgamma-treated conditions; by mass spectrometry analysis of HLA Class I bound peptides. Profound changes in the overall epitope profile presented on HLA Class I molecules were observed.
We studied processing and presentation of three NY-ESO-1 HLA-Cw3 restricted epitopes by melanoma cell lines. Using specific T-lymphocyte clones, we examined presentation of each epitope following processing through proteasome subtypes, and found differences in all three instances. We further investigated processing of these epitopes by selective inhibition of the IP catalytic subunit LMP7 by siRNA knockdown, or small molecule inhibition.
In vivo, we demonstrate that melanoma cells can be induced to switch proteasome subtype following treatments which induce IFNgamma at the tumour site.
Our data demonstrate broad changes in epitopes presented by melanoma cells under inflammatory versus non-inflammatory conditions. These results illustrate a little-studied mechanism of immune escape by tumour cells. Awareness of how individual cancer epitopes are processed by melanoma cells is therefore critical to inform development of future therapies which involve cancer vaccination, adoptive T-lymphocyte transfer, or combination treatments including these.